Intelligence · Sponsor directory
Pharma & Biotech Companies
Premium sponsor intelligence profiles with pipeline dashboards, drug portfolios, patent hubs, and competitive peer analysis — built for BD, licensing, and research teams.
Quick answer
NovaPharmaNews profiles 1,769 pharmaceutical and biotech companies with SEC identifiers, headquarters, therapeutic focus, and cross-links to pipeline programs, drug portfolios, and US patents. Search by legal name, brand name, or ticker for BD, licensing, and competitive intelligence.
-
Ongentys
-
Only For Children
Only For Children Pharmaceuticals
-
Opdivo
-
Oral B Laboratories
Oral B Laboratories Pty Ltd
-
Orencia
-
Oresund Pharma ApS
-
Orexigen Therapeutics Ireland
Orexigen Therapeutics Ireland Limited
-
Orfadin
-
Oriental Neurosurgery Evidence-Based-Study
Oriental Neurosurgery Evidence-Based-Study Team
-
Orkedia
-
Orladeyo
-
Orphalan
-
Orphazyme A/S
-
Ostabalo
-
Otezla
-
Otsuka Pharmaceutical Netherlands
Otsuka Pharmaceutical Netherlands B.V.
-
Ou Bai, MD/PHD
-
PERRIGO AUSTRALIA PTY
PERRIGO AUSTRALIA PTY LIMITED
-
Paion Pharma
Paion Pharma GmbH
-
Paratek Ireland
Paratek Ireland Limited
-
Parmodia
-
Parnell Technologies (UK)
Parnell Technologies (UK) Limited
-
Parsabiv
-
Passauer Pharma
Passauer Pharma GmbH
Frequently asked questions
What is the NovaPharmaNews companies directory?
It is a searchable index of 1,769 pharma and biotech organizations — public and private — with ticker symbols, HQ location, company type, and counts of linked pipeline programs, drugs, and patents.
Where does company data come from?
Profiles combine SEC EDGAR filings, ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page for attribution and refresh cadence. Directory content is for professional reference, not investment advice.
How do I find a company by ticker or name?
Use the search box — it matches legal name, common name, and stock ticker. Each company profile links to its pipeline programs, marketed drugs, and related patents where available.